Expression of tissue inhibitor of metalloproteinase-1, -2, and -3 during neointima formation in organ cultures of human saphenous vein.

Degradation of the extracellular basement membrane is implicated in atherosclerosis, restenosis after angioplasty, and intimal thickening of vein grafts. Upregulation of metalloproteinase (MMP)-2 and MMP-9 accompanies neointima formation in cholesterol-fed rabbits, in rat and pig models of angioplasty, and in organ cultures of human saphenous veins. MMPs are inhibited by binding to tissue inhibitors of MMPs (TIMPs). Relatively little is known about their regulation in relationship to neointima formation; thus, we investigated TIMP expression in the organ culture model. Qualitative reverse transcriptase-polymerase chain reaction of mRNA extracted from veins showed that TIMP-1, TIMP-2, and TIMP-3 are each expressed before and after culture. Zymography revealed that TIMP-1 was the most abundant TIMP secreted and that its secretion increased dramatically between 0 to 2 and 12 to 14 days of culture. An enzyme-linked immunosorbent assay showed that TIMP-1 secretion increased from 3.2+/-1.5 (mean+/-SE) to 32+/-6 ng/mg wet weight per day (n=5, P<0.01). Immunocytochemical testing localized the increased expression of TIMP-1 to neointimal smooth muscle cells. Although less abundant, TIMP-2 secretion also increased from 0.8+/-0. 3 to 4.7+/-0.2 ng/mg wet weight per day (n=5, P<0.001), and tissue levels increased from 33+/-7 to 150+/-70 ng/mg wet weight (P<0.05). TIMP-2 was also immunolocalized to neointimal smooth muscle cells and their surrounding matrix. TIMP-3 was not secreted but was detected variably and constitutively in tissue extracts (160+/-120 and 170+/-100 ng/mg wet weight [n=9] on days 2 and 14, respectively). TIMP-3 was found in the cells and extracellular matrix of the media and adventitia before culture and to a lesser extent in the neointima after 14 days of culture. Rates of total TIMP secretion on day 14 exceeded those of MMP-2 and MMP-9 (10.6+/-1.9 and 15.6+/-2.3 ng/mg wet weight per day, respectively). Consistent with this, in situ zymography showed that MMP gelatinase activity was highly localized to cell bodies in the media and neointima. Secretion of TIMP-1 and TIMP-2 is greatly increased during neointima formation in human saphenous veins. TIMP-1 is readily released, whereas TIMP-2 remains partially attached and TIMP-3 exclusively attached to the extracellular matrix. Regulation of TIMP expression is therefore an important determinant of net MMP activity during neointima formation, restricting it to the pericellular environment.

[1]  G. Angelini,et al.  Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. , 1998, Human gene therapy.

[2]  G. Angelini,et al.  Prevention of vein graft failure: potential applications for gene therapy. , 1997, Cardiovascular research.

[3]  A. Zalewski,et al.  Remodeling of autologous saphenous vein grafts. The role of perivascular myofibroblasts. , 1997, Circulation.

[4]  A. Clowes,et al.  Plasminogen activator inhibitor type 1 and tissue inhibitor of metalloproteinases-2 increase after arterial injury in rats. , 1997, Circulation research.

[5]  A. Newby,et al.  Increased secretion of gelatinases A and B from the aortas of cholesterol fed rabbits: relationship to lesion severity. , 1997, Atherosclerosis.

[6]  S. George,et al.  Surgical preparative injury and neointima formation increase MMP-9 expression and MMP-2 activation in human saphenous vein. , 1997, Cardiovascular research.

[7]  G. Wilkinson,et al.  Development of recombinant adenoviruses that drive high level expression of the human metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 genes: characterization of their infection into rabbit smooth muscle cells and human MCF-7 adenocarcinoma cells. , 1996, Matrix biology : journal of the International Society for Matrix Biology.

[8]  M. Davies,et al.  Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. , 1996, Circulation research.

[9]  M. Reidy,et al.  The role of plasminogen, plasminogen activators, and matrix metalloproteinases in primate arterial smooth muscle cell migration. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[10]  A. Bowcock,et al.  Structure and Characterization of the Human Tissue Inhibitor of Metalloproteinases-2 Gene* , 1996, The Journal of Biological Chemistry.

[11]  A. Clowes,et al.  Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. , 1996, Circulation research.

[12]  M. Alavi,et al.  Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in rabbit aortic neointima after selective de-endothelialization. , 1996, Atherosclerosis.

[13]  A. Newby,et al.  Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinases-1, -2, and -3 in rabbit aortic smooth muscle cells. , 1996, The Biochemical journal.

[14]  M. Ferguson,et al.  Expression of collagen, interstitial collagenase, and tissue inhibitor of metalloproteinases-1 in restenosis after carotid endarterectomy. , 1996, The American journal of pathology.

[15]  K. Iwata,et al.  Immunohistochemical analysis of TIMP-3 expression in degenerative retinal disease , 1996 .

[16]  S. George,et al.  An essential role for platelet-derived growth factor in neointima formation in human saphenous vein in vitro. , 1996, Atherosclerosis.

[17]  S. Apte,et al.  The Gene Structure of Tissue Inhibitor of Metalloproteinases (TIMP)-3 and Its Inhibitory Activities Define the Distinct TIMP Gene Family (*) , 1995, The Journal of Biological Chemistry.

[18]  A. Strongin,et al.  Mechanism Of Cell Surface Activation Of 72-kDa Type IV Collagenase , 1995, The Journal of Biological Chemistry.

[19]  P. Libby,et al.  Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[21]  G. Murphy,et al.  Structure-function relationships in the tissue inhibitors of metalloproteinases. , 1994, American journal of respiratory and critical care medicine.

[22]  M. Reidy,et al.  Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. , 1994, Circulation research.

[23]  M. Reidy,et al.  Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. , 1994, Journal of vascular surgery.

[24]  E. Lakatta,et al.  Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. , 1994, Circulation research.

[25]  P. Libby,et al.  Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. , 1994, Circulation research.

[26]  A. Ferrando,et al.  Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family. , 1994, Cancer research.

[27]  R. Khokha,et al.  Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. , 1994, The Journal of biological chemistry.

[28]  V. V. van Hinsbergh,et al.  Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. , 1993, The Biochemical journal.

[29]  G. Angelini,et al.  Surgical preparation induces injury and promotes smooth muscle cell proliferation in a culture of human saphenous vein. , 1993, Cardiovascular research.

[30]  R. Ross The pathogenesis of atherosclerosis: a perspective for the 1990s , 1993, Nature.

[31]  A. Newby,et al.  Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. , 1992, The Biochemical journal.

[32]  J. Heath,et al.  Involvement of AP1 and PEA3 binding sites in the regulation of murine tissue inhibitor of metalloproteinases-1 (TIMP-1) transcription. , 1992, Biochimica et biophysica acta.

[33]  M. Cockett,et al.  The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. , 1992, The Biochemical journal.

[34]  R. Hembry,et al.  The purification of tissue inhibitor of metalloproteinases-2 from its 72 kDa progelatinase complex. Demonstration of the biochemical similarities of tissue inhibitor of metalloproteinases-2 and tissue inhibitor of metalloproteinases-1. , 1991, The Biochemical journal.

[35]  G. Angelini,et al.  Intimal proliferation in an organ culture of human saphenous vein. , 1990, The American journal of pathology.

[36]  L. Liotta,et al.  Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. , 1990, The Journal of biological chemistry.

[37]  G. Angelini,et al.  The future of saphenous vein as a coronary artery bypass conduit. , 1989, European heart journal.

[38]  K. Fujimori,et al.  Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. , 1987, Cancer research.

[39]  P. Stephens,et al.  Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity , 1985, Nature.

[40]  D. Bowyer,et al.  Endothelial injury and healing in vitro. Studies using an organ culture system. , 1985, The American journal of pathology.

[41]  R. Hembry,et al.  Immunolocalization of tissue inhibitor of metalloproteinases (TIMP) in human cells. Characterization and use of a specific antiserum. , 1985, Journal of cell science.

[42]  M. Bourassa,et al.  Atherosclerosis and late closure of aortocoronary saphenous vein grafts: sequential angiographic studies at 2 weeks, 1 year, 5 to 7 years, and 10 to 12 years after surgery. , 1983, Circulation.

[43]  W. Rutter,et al.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.

[44]  G. Angelini,et al.  Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits SMC migration and neointima formation in human saphenous vein , 1998 .

[45]  A. Clowes,et al.  Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[46]  J. Thyberg Differentiated properties and proliferation of arterial smooth muscle cells in culture. , 1996, International review of cytology.

[47]  M. Reidy,et al.  Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. , 1996, Circulation research.

[48]  ScienceDirect Matrix biology : journal of the International Society for Matrix Biology. , 1994 .

[49]  R. RPauly,et al.  Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. , 1994 .

[50]  H. Birkedal‐Hansen,et al.  Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.